BSE filing, NSE: SAMRATPH. Summary written from the filing by ALFA Finder's alert engine.
Samrat Pharmachem Ltd: key numbers
- Share price
- ₹266.00
- Market cap
- ₹82.19 Cr
- Revenue (annual)
- ₹289.7 Cr
- Net profit (annual)
- ₹-3.31 Cr
- P/E (TTM)
- -37.2×Sector 46.1×
- Promoter holding
- 49.09%+0.00% QoQ
- FII holding
- 3.24%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Samrat Pharmachem Ltd
All →Samrat Pharmachem Other Announcement
Samrat Pharmachem Ltd filed its quarterly shareholding pattern as mandated by SEBI regulations. This is a routine compliance disclosure detailing the company's ownership structure.
Samrat Pharmachem Board Meeting Date
Samrat Pharmachem will hold a board meeting on November 14, 2026, to consider its unaudited quarterly financial results for the period ended September 2026.
Samrat Pharmachem Annual General Meeting
Samrat Pharmachem Limited held its 34th Annual General Meeting on September 23, 2026. The meeting successfully transacted the business items outlined in the prior meeting notice.
Samrat Pharmachem Annual General Meeting
Samrat Pharmachem will hold its 34th Annual General Meeting on September 23, 2026, via video conferencing. The company also announced book closure dates for shareholders.
Samrat Pharmachem Annual Report
Samrat Pharmachem filed its 34th Annual Report for FY 2025-26. The company's 34th AGM is scheduled for September 23, 2026, via video conferencing.
Samrat Pharmachem Q1 FY27 Results: Turns Profitable, Net Profit ₹0.9 Cr
Samrat Pharmachem Ltd reported revenue from operations of ₹79.8 Cr (+5.4% YoY) and net profit of ₹0.9 Cr for Q1 FY27.
- Key figure
- Net profit ₹0.9 Cr
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.